Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03644563 · ClinicalTrials.gov registry record
Men and Women Offering Understanding of Throat HPV
A clinical trial of Human Papilloma Virus and Oropharyngeal Cancer, sponsored by Johns Hopkins University.
- Active
- Registry status
- 1,500
- Enrollment target
- 1
- Study location
NCT03644563: Active study of Human Papilloma Virus and Oropharyngeal Cancer, sponsored by Johns Hopkins University.
NCT03644563 is a study of Human Papilloma Virus and Oropharyngeal Cancer that is active but no longer recruiting, run by Johns Hopkins University. The registered enrollment target is 1,500 participants, below the 8,403-participant average among 39 other Human Papilloma Virus trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03644563, a study of Human Papilloma Virus and Oropharyngeal Cancer, is active but no longer recruiting, sponsored by Johns Hopkins University.
- ACTIVE NOT RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will screen people for oncogenic oral Human Papillomavirus (HPV) infection and antibodies to form a cohort of people who may be at increased risk of HPV-oropharyngeal cancer (HPV-OPC). The investigators will follow these individuals prospectively to evaluate oncogenic oral HPV persistence, risk factors, and biomarkers for persistence.
Primary Outcome
To explore the effects of biologic (microbiome, oral immune response, biologic sex) risk factors for oncogenic oral HPV persistence
Conditions Studied
Study Locations (1)
Maryland
- Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2017-04-03 |
| Est. Completion | 2028-06 |
What the registry record for NCT03644563 still lists
NCT03644563 is an observational study that tracks outcomes without assigning an intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, below the 8,403-participant average among 39 other Human Papilloma Virus trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Human Papilloma Virus appearing as the primary indexed condition, and to 0 interventions.
NCT03644563 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT03644563 about?
NCT03644563 is a clinical study titled "Men and Women Offering Understanding of Throat HPV". This study will screen people for oncogenic oral Human Papillomavirus (HPV) infection and antibodies to form a cohort of people who may be at increased risk of HPV-oropharyngeal cancer (HPV-OPC). The investigators will follow these individuals prospectively to evaluate oncogenic oral HPV persistence...
What is the current status of trial NCT03644563?
This trial is currently active not recruiting. The enrollment target is 1,500 participants. The study started on 2017-04-03. Estimated completion is 2028-06.
What conditions does trial NCT03644563 study?
This clinical trial studies the following conditions: Human Papilloma Virus, Oropharyngeal Cancer.
Who is sponsoring clinical trial NCT03644563?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03644563 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papilloma Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03644563's enrollment target sits among peer trials
1,500 5th of 39 higher than 35 of 39 other Human Papilloma Virus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Human Papilloma Virus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine
RECRUITING · NA
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
Multidimensional and Multimodal Profiling of Oropharyngeal Carcinoma
RECRUITING
-
Merck IIT: RRP Pembro and Lenvatinib
RECRUITING · Early Phase 1
-
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI